{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:41:45Z","timestamp":1791448905934,"version":"4.3.3"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":1315,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.4103\/ijmm.ijmm_17_278","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T02:46:05Z","timestamp":1518662765000},"page":"340-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Optimisation of Antimicrobial Dosing Based on Pharmacokinetic and Pharmacodynamic Principles"],"prefix":"10.1016","volume":"35","author":[{"given":"Grace Si","family":"Ru Hoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Xin","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Lay-Hoon","family":"Kwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.4103\/ijmm.IJMM_17_278_bib1","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1086\/519256","article-title":"Optimizing drug exposure to minimize selection of antibiotic resistance","volume":"45","author":"Olofsson","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_17_278_bib2","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: Defining antibiotic levels in Intensive Care Unit patients: Are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_17_278_bib3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.4103\/ijmm.IJMM_17_278_bib4","first-page":"3178","article-title":"Therapeutic drug monitoring of the \u03b2-lactam antibiotics: What is the evidence and which patients should we be using it for?","volume":"70","author":"Huttner","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.4103\/ijmm.IJMM_17_278_bib5","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.clinthera.2016.06.015","article-title":"Pharmacokinetic and pharmacodynamic principles of anti-infective dosing","volume":"38","author":"Onufrak","year":"2016","journal-title":"Clin Ther"},{"key":"10.4103\/ijmm.IJMM_17_278_bib6","doi-asserted-by":"crossref","first-page":"R206","DOI":"10.1186\/cc10441","article-title":"Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of \u03b2-lactams","volume":"15","author":"Gon\u00e7alves-Pereira","year":"2011","journal-title":"Crit Care"},{"key":"10.4103\/ijmm.IJMM_17_278_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient \u2013 Concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.4103\/ijmm.IJMM_17_278_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ccc.2010.09.006","article-title":"Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock","volume":"27","author":"Varghese","year":"2011","journal-title":"Crit Care Clin"},{"key":"10.4103\/ijmm.IJMM_17_278_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","article-title":"The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients","volume":"50","author":"Ulldemolins","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.4103\/ijmm.IJMM_17_278_bib10","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/bmj.38985.398704.7C","article-title":"Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: Analysis of data from the saline versus albumin fluid evaluation (SAFE) study","volume":"333","author":"Finfer","year":"2006","journal-title":"BMJ"},{"key":"10.4103\/ijmm.IJMM_17_278_bib11","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2165\/00003088-200746120-00003","article-title":"Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy","volume":"46","author":"Pea","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.4103\/ijmm.IJMM_17_278_bib12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.diagmicrobio.2014.04.007","article-title":"How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?","volume":"79","author":"Felton","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.4103\/ijmm.IJMM_17_278_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11318140-000000000-00000","article-title":"Augmented renal clearance: Implications for antibacterial dosing in the critically ill","volume":"49","author":"Udy","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.4103\/ijmm.IJMM_17_278_bib14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/CCM.0000000000000029","article-title":"Augmented renal clearance in the ICU: Results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations*","volume":"42","author":"Udy","year":"2014","journal-title":"Crit Care Med"},{"key":"10.4103\/ijmm.IJMM_17_278_bib15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: An update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl D","key":"10.4103\/ijmm.IJMM_17_278_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jac\/31.suppl_D.149","article-title":"Post-antibiotic effects in experimental infection models: Relationship to in-vitro phenomena and to treatment of infections in man","volume":"31","author":"Craig","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.4103\/ijmm.IJMM_17_278_bib17","doi-asserted-by":"crossref","first-page":"1-0","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_17_278_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It\u2019s not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_17_278_bib19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/infdis\/157.2.287","article-title":"In vivo postantibiotic effect in a thigh infection in neutropenic mice","volume":"157","author":"Vogelman","year":"1988","journal-title":"J Infect Dis"},{"key":"10.4103\/ijmm.IJMM_17_278_bib20","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1128\/AAC.26.5.678","article-title":"Postantibiotic effect of imipenem on Pseudomonas aeruginosa","volume":"26","author":"Bustamante","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl A","key":"10.4103\/ijmm.IJMM_17_278_bib21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/jac\/24.suppl_A.225","article-title":"The postantibiotic effect of meropenem and imipenem on selected bacteria","volume":"24","author":"Nadler","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"10.4103\/ijmm.IJMM_17_278_bib22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/jac\/35.5.585","article-title":"Control-related effective regrowth time and post-antibiotic effect of meropenem on gram-negative bacteria studied by bioluminescence and viable counts","volume":"35","author":"Hanberger","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.4103\/ijmm.IJMM_17_278_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_17_278_bib24","first-page":"94","article-title":"Continuous infusion vs. Bolus dosing: Implications for beta-lactam antibiotics","volume":"78","author":"Mohd Hafiz","year":"2012","journal-title":"Minerva Anestesiol"},{"key":"10.4103\/ijmm.IJMM_17_278_bib25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1586\/eri.13.44","article-title":"Extended or continuous versus short-term intravenous infusion of cephalosporins: A meta-analysis","volume":"11","author":"Korbila","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.4103\/ijmm.IJMM_17_278_bib26","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/cid\/cis857","article-title":"Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin\/tazobactam: A systematic review and meta-analysis","volume":"56","author":"Falagas","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_17_278_bib27","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1097\/CCM.0b013e3181a0054d","article-title":"A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"10.4103\/ijmm.IJMM_17_278_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/1471-2334-11-181","article-title":"Does prolonged \u03b2-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials","volume":"11","author":"Tamma","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.4103\/ijmm.IJMM_17_278_bib29","first-page":"CD008481","article-title":"Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections","author":"Shiu","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.4103\/ijmm.IJMM_17_278_bib30","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(05)70218-8","article-title":"Continuous versus intermittent intravenous administration of antibiotics: A meta-analysis of randomised controlled trials","volume":"5","author":"Kasiakou","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.4103\/ijmm.IJMM_17_278_bib31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijantimicag.2014.01.027","article-title":"Prolonged infusion versus intermittent boluses of \u03b2-lactam antibiotics for treatment of acute infections: A meta-analysis","volume":"43","author":"Teo","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.4103\/ijmm.IJMM_17_278_bib32","doi-asserted-by":"crossref","first-page":"e0116769","DOI":"10.1371\/journal.pone.0116769","article-title":"Clinical outcomes with alternative dosing strategies for piperacillin\/tazobactam: A systematic review and meta-analysis","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"key":"10.4103\/ijmm.IJMM_17_278_bib33","doi-asserted-by":"crossref","first-page":"R279","DOI":"10.1186\/cc13134","article-title":"Optimal dosing of antibiotics in critically ill patients by using continuous\/extended infusions: A systematic review and meta-analysis","volume":"17","author":"Chant","year":"2013","journal-title":"Crit Care"},{"key":"10.4103\/ijmm.IJMM_17_278_bib34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/2110-5820-2-37","article-title":"Continuous beta-lactam infusion in critically ill patients: The clinical evidence","volume":"2","author":"Abdul-Aziz","year":"2012","journal-title":"Ann Intensive Care"},{"key":"10.4103\/ijmm.IJMM_17_278_bib35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1440-1681.2012.05715.x","article-title":"B-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: A structured review","volume":"39","author":"Sinnollareddy","year":"2012","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.4103\/ijmm.IJMM_17_278_bib36","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","article-title":"Beta-lactam infusion in severe sepsis (BLISS): A prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis","volume":"42","author":"Abdul-Aziz","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.4103\/ijmm.IJMM_17_278_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2125.2011.04080.x","article-title":"Therapeutic drug monitoring of antimicrobials","volume":"73","author":"Roberts","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.4103\/ijmm.IJMM_17_278_bib38","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.medin.2015.07.009","article-title":"Antibiotic dose optimization in critically ill patients","volume":"39","author":"Cotta","year":"2015","journal-title":"Med Intensiva"},{"key":"10.4103\/ijmm.IJMM_17_278_bib39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ccm.2011.05.006","article-title":"Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumonia","volume":"32","author":"Housman","year":"2011","journal-title":"Clin Chest Med"},{"key":"10.4103\/ijmm.IJMM_17_278_bib40","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.4103\/ijmm.IJMM_17_278_bib41","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/cir124","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: Support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_17_278_bib42","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1128\/AAC.05609-11","article-title":"Vancomycin AUC24\/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization","volume":"56","author":"Brown","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_17_278_bib43","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/AAC.01485-12","article-title":"Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia","volume":"57","author":"Holmes","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_17_278_bib44","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijantimicag.2012.10.015","article-title":"Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock","volume":"41","author":"Zelenitsky","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.4103\/ijmm.IJMM_17_278_bib45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.4103\/ijmm.IJMM_17_278_bib46","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2146\/ajhp060047","article-title":"Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters","volume":"63","author":"Murphy","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"10.4103\/ijmm.IJMM_17_278_bib47","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_17_278_bib48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijantimicag.2005.11.009","article-title":"Loading dose of vancomycin in critically ill patients: 15 mg\/kg is a better choice than 500 mg","volume":"27","author":"Mohammedi","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.4103\/ijmm.IJMM_17_278_bib49","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1128\/JCM.01388-06","article-title":"Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period","volume":"44","author":"Wang","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.4103\/ijmm.IJMM_17_278_bib50","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1345\/aph.1R420","article-title":"Review of continuous-infusion vancomycin","volume":"47","author":"DiMondi","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.4103\/ijmm.IJMM_17_278_bib51","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijantimicag.2015.04.013","article-title":"Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous versus intermittent infusion","volume":"46","author":"Hanrahan","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.4103\/ijmm.IJMM_17_278_bib52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijantimicag.2015.10.019","article-title":"Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis","volume":"47","author":"Hao","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.4103\/ijmm.IJMM_17_278_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkr442","article-title":"Continuous versus intermittent infusion of vancomycin for the treatment of gram-positive infections: Systematic review and meta-analysis","volume":"67","author":"Cataldo","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"10.4103\/ijmm.IJMM_17_278_bib54","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1086\/314059","article-title":"Clinical pharmacology of the fluoroquinolones: Studies in human dynamic\/kinetic models","volume":"31","author":"Schentag","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_17_278_bib55","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_17_278_bib56","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0924-8579(00)00253-3","article-title":"Pharmacokinetic\/pharmacodynamic predictors of time to clinical resolution in patients with acute bacterial exacerbations of chronic bronchitis treated with a fluoroquinolone","volume":"16","author":"Meinl","year":"2000","journal-title":"Int J Antimicrob Agents"},{"key":"10.4103\/ijmm.IJMM_17_278_bib57","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/jac\/dkq211","article-title":"Support for higher ciprofloxacin AUC 24\/MIC targets in treating Enterobacteriaceae bloodstream infection","volume":"65","author":"Zelenitsky","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl","key":"10.4103\/ijmm.IJMM_17_278_bib58","first-page":"63","article-title":"Killing and regrowth of bacteria in vitro: A review","volume":"74","author":"Craig","year":"1990","journal-title":"Scand J Infect Dis"},{"key":"10.4103\/ijmm.IJMM_17_278_bib59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0891-5520(03)00057-6","article-title":"Pharmacodynamics and dosing of aminoglycosides","volume":"17","author":"Turnidge","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.4103\/ijmm.IJMM_17_278_bib60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ccc.2010.11.006","article-title":"Optimizing aminoglycoside use","volume":"27","author":"Craig","year":"2011","journal-title":"Crit Care Clin"},{"key":"10.4103\/ijmm.IJMM_17_278_bib61","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2165\/00003495-200161060-00001","article-title":"Aminoglycoside adaptive resistance: Importance for effective dosage regimens","volume":"61","author":"Barclay","year":"2001","journal-title":"Drugs"},{"key":"10.4103\/ijmm.IJMM_17_278_bib62","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","article-title":"Aminoglycosides: Nephrotoxicity","volume":"43","author":"Mingeot-Leclercq","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_17_278_bib63","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1128\/AAC.21.5.721","article-title":"Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients","volume":"21","author":"Schentag","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_17_278_bib64","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/jac\/24.3.281","article-title":"Determinants of efficacy and toxicity of aminoglycosides","volume":"24","author":"Mattie","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"10.4103\/ijmm.IJMM_17_278_bib65","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1128\/AAC.35.3.399","article-title":"Once-daily aminoglycoside therapy","volume":"35","author":"Gilbert","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijmm.IJMM_17_278_bib66","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/jac\/37.4.645","article-title":"A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses","volume":"37","author":"Munckhof","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.4103\/ijmm.IJMM_17_278_bib67","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2146\/ajhp140564","article-title":"Once-daily aminoglycoside dosing: An update on current literature","volume":"72","author":"Stankowicz","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"10.4103\/ijmm.IJMM_17_278_bib68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00007691-199902000-00010","article-title":"Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: A cost-effectiveness analysis","volume":"21","author":"van Lent-Evers","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.4103\/ijmm.IJMM_17_278_bib69","series-title":"Drug Prescribing in Renal Failure: Dosage Guidelines in Adults","author":"Aronoff","year":"1999"},{"key":"10.4103\/ijmm.IJMM_17_278_bib70","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1525-139X.2008.00554.x","article-title":"Aminoglycosides in hemodialysis patients: Is the current practice of post dialysis dosing appropriate?","volume":"22","author":"O\u2019Shea","year":"2009","journal-title":"Semin Dial"},{"key":"10.4103\/ijmm.IJMM_17_278_bib71","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1007\/s00134-013-3088-4","article-title":"Clinical implications of antibiotic pharmacokinetic principles in the critically ill","volume":"39","author":"Udy","year":"2013","journal-title":"Intensive Care Med"},{"key":"10.4103\/ijmm.IJMM_17_278_bib72","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2014.01.015","article-title":"The influence of acute kidney injury on antimicrobial dosing in critically ill patients: Are dose reductions always necessary?","volume":"79","author":"Blot","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.4103\/ijmm.IJMM_17_278_bib73","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrneph.2011.12","article-title":"Antibiotic dosing in critically ill patients with acute kidney injury","volume":"7","author":"Eyler","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.4103\/ijmm.IJMM_17_278_bib74","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/jac\/dkp302","article-title":"A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: Do current studies supply sufficient data?","volume":"64","author":"Li","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.4103\/ijmm.IJMM_17_278_bib75","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1592\/phco.29.5.562","article-title":"Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis","volume":"29","author":"Heintz","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.4103\/ijmm.IJMM_17_278_bib76","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/QCO.0000000000000206","article-title":"Optimizing dosing of antibiotics in critically ill patients","volume":"28","author":"Parker","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_17_278_bib77","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2165\/00003088-200645080-00001","article-title":"Antibacterial dosing in intensive care: Pharmacokinetics, degree of disease and pharmacodynamics of sepsis","volume":"45","author":"Roberts","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.4103\/ijmm.IJMM_17_278_bib78","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.clpt.6100381","article-title":"Dosing in obesity: A simple solution to a big problem","volume":"82","author":"Han","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.4103\/ijmm.IJMM_17_278_bib79","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s13546-015-1060-8","article-title":"Optimization of antibiotic therapy in the obese, critically ill patient","volume":"24","author":"Hites","year":"2015","journal-title":"R\u00e9animation"},{"key":"10.4103\/ijmm.IJMM_17_278_bib80","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1086\/514505","article-title":"Antimicrobial dosing in obese patients","volume":"25","author":"Wurtz","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_17_278_bib81","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1586\/14787210.2014.912942","article-title":"Dosing of antibacterial agents in obese adults: Does one size fit all?","volume":"12","author":"Payne","year":"2014","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085720303303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085720303303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T19:15:25Z","timestamp":1759346125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085720303303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0255085720303303"],"URL":"https:\/\/doi.org\/10.4103\/ijmm.ijmm_17_278","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimisation of Antimicrobial Dosing Based on Pharmacokinetic and Pharmacodynamic Principles","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4103\/ijmm.IJMM_17_278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Indian Journal of Medical Microbiology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}